Price Changes for 137 Anti-Cancer Medicines Take Effect on November 9 Under NPPA Margin Cap

NEW DELHI, November 7, 2026 — Revised prices for 137 non-scheduled anti-cancer medicines are due to take effect across India on Monday, November 9, under a trade-margin cap imposed by the National Pharmaceutical Pricing Authority (NPPA). The government says companies had reported revised maximum retail prices for 120 of the identified medicines by November 4, with reductions averaging 20% to 70% and estimated savings of ₹3,357.49 crore for patients.

The measure applies a 30% cap on trade margins for the identified medicines. The NPPA announced the intervention on October 17, using powers under the Drugs (Prices Control) Order, 2013, to address what the government described as excessive mark-ups in the supply chain. The revised prices are scheduled to become effective on November 9, giving manufacturers, distributors, hospitals and retail pharmacies a defined date for the new pricing arrangements.

The Department of Pharmaceuticals said on November 6 that 70 companies had reported revised maximum retail prices for 120 drugs by November 4. It said the highest reported reduction was 96.45%. That figure refers to the largest reduction reported for an individual medicine; it should not be interpreted as the reduction for every drug or as the average cut across the full list. The government’s stated average range is 20% to 70% for the reported revisions.

A trade margin is the difference between the price at which a medicine is supplied through the distribution chain and the price at which it is sold to the patient, subject to the applicable pricing rules. A cap on the margin limits how much can be added through the distribution chain for the medicines covered by the order. It is not the same as setting one uniform price for every cancer medicine, because the products have different manufacturers, formulations, strengths and existing prices.

The NPPA’s action covers 137 non-scheduled anti-cancer medicines, including certain patented drugs. Non-scheduled medicines are not subject to the same ceiling-price mechanism used for drugs listed under the National List of Essential Medicines. The trade-margin intervention is intended to address high mark-ups in this segment, where the government said differences between retail and hospital prices and the size of distribution margins had become a concern.

The department said the list includes medicines used in immunotherapy and treatments for several cancers, as well as drugs such as denosumab, pegfilgrastim and bevacizumab. These medicines have different clinical indications and are not interchangeable. Patients should not change a prescribed treatment or substitute a medicine solely on the basis of a price comparison; any therapeutic decision must remain with the treating clinician.

Patients and caregivers should check the printed maximum retail price on the pack and compare it with the amount charged on the bill after the revised prices take effect. The actual amount paid can also depend on the formulation, strength, pack size and the pharmacy or hospital’s billing arrangements. The 30% trade-margin cap does not mean that every patient will see the same percentage reduction, and the reported range does not guarantee a specific saving on an individual prescription.

The government’s November 6 update said companies had reported revised MRPs for 120 of the 137 medicines. That leaves a gap between the total number covered by the order and the number for which the department said revised prices had been reported by November 4. Further compliance updates will be important to establish whether all manufacturers and sellers have implemented the required changes by the effective date.

Patients who believe they have been charged above the applicable revised MRP should retain the prescription, medicine packaging and itemised bill. They can use those documents when seeking clarification from the pharmacy, hospital or relevant drug-price authority. The exact complaint route may depend on the nature of the medicine and the pricing issue; patients should consult the NPPA or Department of Pharmaceuticals for the official process rather than relying on informal online claims.

The government said the intervention followed a review of mark-ups and pricing differences in the market for non-scheduled anti-cancer medicines. It cited an earlier trade-margin rationalisation exercise in 2019 that covered 42 non-scheduled anti-cancer drugs. The new order extends the approach to a larger group of medicines and includes products that had not been covered by the earlier intervention.

Medicines used in cancer treatment can be expensive, particularly when patients require repeated cycles, long-term therapy or combinations of drugs. The cost of treatment can also include diagnostics, hospital services, supportive medicines and travel. A reduction in the MRP of a covered medicine can ease one part of the expense, but it does not by itself determine the total cost of care or remove differences in access between hospitals and regions.

There are also implementation questions. Authorities will need to monitor whether revised prices are reflected across the distribution chain, whether old inventory is billed at the correct price and whether patients can identify the medicines covered by the order. Manufacturers and distributors will need to update their pricing information and ensure that pharmacies and hospitals have the correct details.

The NPPA action should therefore be judged on actual implementation rather than the headline percentage alone. The government’s reported savings are estimates based on the revised prices submitted by companies; the realised benefit will depend on the number of patients receiving the medicines, the quantities used and the prices ultimately charged.

For now, the confirmed change is the scheduled November 9 start of the 30% trade-margin cap for the 137 listed non-scheduled anti-cancer medicines. The government has reported revised MRPs for 120 of those drugs and an estimated savings figure. Patients should check the exact medicine and pack price after the effective date, while further compliance disclosures will show whether the revised rates have been implemented across the market.